Alvotech reports record revenues and adjusted ebitda for the second quarter and first six months of 2024

Alvotech (nasdaq: alvo, or the “company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summary of recent corporate highlights.
ALVO Ratings Summary
ALVO Quant Ranking